Law et al. 24 proposed that the NRG1-ErbB4 signaling system may be a potential therapeutic target for schizophrenia with a special reference to phosphoinositide 3-kinase-p110δ inhibitors. The gene discussed is PIK3CD; the disease is schizophrenia.